BrainsWay Reports Strong 12-Month Durability for SWIFT™ Deep TMS in Depression
Summary
BrainsWay announced positive 12-month durability data for its SWIFT™ Deep TMS protocol for Major Depressive Disorder, showing over 80% remission and significant functional improvement.
Key Events
-
Strong 12-Month Durability Data
Over 80% of patients treated with the SWIFT™ protocol achieved remission through the 12-month follow-up period for Major Depressive Disorder.
-
Significant Functional Improvement
Severe functional impairment decreased dramatically from 85% at baseline to 0% at 12 months, indicating a real-world impact on patient well-being.
-
Reduced Need for Further Intervention
Less than 25% of patients required a change in medication or another course of TMS within the 12-month period to treat their depression.
-
Validation of FDA-Cleared Protocol
The data reinforces the long-term efficacy of the SWIFT™ Deep TMS protocol, which received FDA clearance in September 2025.
Analysis
This filing provides crucial long-term efficacy data for BrainsWay's FDA-cleared SWIFT™ Deep TMS protocol. Demonstrating sustained remission and functional recovery over a full year is a significant validation for the treatment, enhancing its appeal to patients, providers, and potentially strengthening its position for broader reimbursement and market adoption. This data reinforces the company's leadership in noninvasive neurostimulation for mental health.
At the time of this filing, BWAY was trading at $14.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $571.6M. The 52-week trading range was $5.11 to $17.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.